Golimumab (Simponi Aria®)

Simponi Aria (golimumab) is covered only for FDA‑approved indications (adult moderately‑to‑severely active RA, active psoriatic arthritis, adult active ankylosing spondylitis, and active polyarticular JIA/related juvenile diagnoses); non‑FDA uses are excluded. Coverage requires indication‑specific prior therapy (e.g., RA: 3‑month trial of ≥1 biologic or ≥1 conventional synthetic DMARD; JIA: trial of another medication or documented aggressive disease), prescription/consultation by a rheumatologist (or dermatologist for psoriatic arthritis), IV dosing per label (adults 2 mg/kg, pediatrics 80 mg/m2 at weeks 0 and 4 then no more often than every 8 weeks), a 3‑month initial approval and 12‑month renewals with documented clinical response.

"Simponi Aria is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis."

Sign up to see full coverage criteria, indications, and limitations.